You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Details for Patent: 11,324,753

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,324,753 protect, and when does it expire?

Patent 11,324,753 protects QELBREE and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 11,324,753

Title:	Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Abstract:	The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
Inventor(s):	Breder; Christopher D. (Bethesda, MD)
Assignee:	Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:	15/615,423
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 11,324,753

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)	⤷ Sign Up
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-002	Apr 2, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)	⤷ Sign Up
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,324,753

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2735934	⤷ Sign Up
European Patent Office	2341912	⤷ Sign Up
Spain	2459322	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2010028207	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.